Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sangamo Therapeutics Inc (NASDAQ:SGMO)

8.70
Delayed Data
As of 3:59pm ET
 -0.65 / -6.95%
Today’s Change
2.65
Today|||52-Week Range
9.65
+185.25%
Year-to-Date
Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes:...
Jun 26 / TheStreet.com - Paid Partner Content
Biotech Movers: Sangamo, Epizyme, Revance
Jun 21 / TheStreet.com - Paid Partner Content
Shark Bites: Move Along, No Volatility to See Here
Jun 22 / TheStreet.com - Paid Partner Content
3 Biotech Stocks That More than Doubled Year to Date
Jun 19 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close9.35
Today’s open9.40
Day’s range8.55 - 9.50
Volume1,312,167
Average volume (3 months)1,242,236
Market cap$764.4M
Dividend yield--
Data as of 3:59pm ET, 06/27/2017

Growth & Valuation

Earnings growth (last year)-75.86%
Earnings growth (this year)-2.94%
Earnings growth (next 5 years)+24.50%
Revenue growth (last year)-50.96%
P/E ratioNM
Price/Sales11.10
Price/Book4.87

Competitors

 Today’s
change
Today’s
% change
RTRXRetrophin Inc-0.70-3.56%
EDITEditas Medicine Inc-0.52-2.90%
NDRMNeuroderm Ltd-1.95-6.41%
MYOVMyovant Sciences Ltd-0.15-1.26%
Data as of 4:00pm ET, 06/27/2017

Financials

Next reporting dateJuly 26, 2017
EPS forecast (this quarter)-$0.26
Annual revenue (last year)$19.4M
Annual profit (last year)-$71.7M
Net profit margin-369.58%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Alexander Macrae
Chief Financial Officer &
Senior Vice President
Kathy Yi
Corporate headquarters
Richmond, California

Forecasts